Ginkgo Bioworks DNA Equity Securities (FV-NI and No Readily Determinable FV) - Cost
Equity Securities (FV-NI and No Readily Determinable FV) - Cost at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's equity securities (fv-ni and no readily determinable fv) - cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's equity securities (FV-NI and no readily determinable FV) - cost?
- Ginkgo Bioworks (DNA) reported equity securities (FV-NI and no readily determinable FV) - cost of $14.7M in Q1 2026.
- How has Ginkgo Bioworks's equity securities (FV-NI and no readily determinable FV) - cost changed year-over-year?
- Ginkgo Bioworks's equity securities (FV-NI and no readily determinable FV) - cost decreased by 54.3% year-over-year, from $32.17M to $14.7M.
- What is the long-term trend for Ginkgo Bioworks's equity securities (FV-NI and no readily determinable FV) - cost?
- Over 3 years (2022 to 2025), Ginkgo Bioworks's equity securities (FV-NI and no readily determinable FV) - cost has grown at a -48.8% compound annual growth rate (CAGR), from $112.19M to $15.07M.